Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Clinical trials and real-world data consistently show significant weight loss from treatment with Ozempic, Semaglutide and Tirzepatide: Unfortunately, weight regain is a well-documented phenomenon after discontinuation of treatment: SURMOUNT 4 trial- Weight regain after stopping Tirzepatide after 36 weeks versus continuation of treatment Beyond weight regain, the discontinuation of GLP-1 agonists may reverse cardiometabolic benefits: Ongoing trials (e.g., SELECT and SURPASS-CVOT) aim to clarify whether continued use is necessary for sustained cardiovascular risk reduction
Slowing how quickly food leaves the stomach, which can help you feel full sooner and for longer
Maida, A., Lamont, B
Instead of activating one receptor, it activates three: GLP-1, GIP, and glucagon
Modern weight management no longer focuses solely on energy balance
US$ 21.31
US$ 20.00
US$ 20.93
US$ 22.71
US$ 24.98
